RT Journal Article
SR Electronic
T1 Antibody response to SARS-CoV-2 infection over six months among Nicaraguan outpatients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.28.21256122
DO 10.1101/2021.04.28.21256122
A1 Fredman González
A1 Omar Zepeda
A1 Christian Toval-Ruiz
A1 Armando Matute
A1 Hernan Vanegas
A1 Nancy Munguia
A1 Edwing Centeno
A1 Yaoska Reyes
A1 Lennart Svensson
A1 Johan Nordgren
A1 Aravinda M. de Silva
A1 Sylvia Becker-Dreps
A1 Lakshmanane Premkumar
A1 Filemón Bucardo
YR 2021
UL http://medrxiv.org/content/early/2021/04/29/2021.04.28.21256122.abstract
AB New information is emerging about SARS-CoV-2 epidemiology and immunity, but little of this information comes from low- and middle-income countries or from patients receiving care in the outpatient setting. The current study investigated the SARS-CoV-2 infection status and antibody responses in 157 patients seeking care for a respiratory disease suggestive of COVID-19 in private healthcare clinics during the first wave (June–October 2020) of infections in Nicaragua. We examined nasal swabs for the presence of viral RNA via RT-PCR and longitudinally collected sera for the changes in SARS-CoV-2 Spike antibody levels over six months. Among patients with confirmed SARS-CoV-2 infections, we evaluated if clinical symptoms were associated with age, hematological parameters and co-morbidities. The combination of PCR and paired serology identified 60 (38%) of the 157 outpatients as acute COVID-19. While both PCR and serology identified the majority (n = 38, 64%) of the acute infections, a notable number of outpatients were identified by RT-qPCR (n = 13, 22%) or by serology (n = 9, 14%) only. During the longitudinal study, we identified 6 new infections by serology among the 97 non-COVID-19 subjects. In conclusion, this study report that more than one third of the outpatients seeking care for acute respiratory disease during the first epidemic wave of SARS-CoV-2 in Nicaragua had an acute mild COVID-19 infection that correlate with prolonged humoral response. This immune response to the RBD antigen, more likely IgG dependent, significantly increased between the acute to convalescent and decay in the late convalescent but still remained seropositive.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFG, OZ, and YR are supported by an award from the NIH-Fogarty International Center [D43TW010923]. SBD and LP are supported by awards from the National Institute of Allergy and Infectious Diseases [K24AI141744 and 1U01AI151788-01, respectively]. LP also receive support from the National Cancer Institute [NCI U54 CA260543-01] FB, JN and LS received support from the Swedish Research Council.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the ethical committee for biomedical research from UNAN-Leon, on May 2020 and amended in September 2020 (FWA00004523/IRB00003342). All patients signed an inform consent and all methods applied in accordance with guidelines and regulations, such as, good clinical and laboratory practices.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article [and/or] its supplementary materials.